These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 16903030)

  • 1. Old customs, ancient lore: the development of custom device law through neglect.
    Klepinski RJ
    Food Drug Law J; 2006; 61(2):237-49. PubMed ID: 16903030
    [No Abstract]   [Full Text] [Related]  

  • 2. Federal preemption of common law tort awards by the Federal Food, Drug, and Cosmetic Act.
    Carrier MK
    Food Drug Law J; 1996; 51(4):509-611. PubMed ID: 11797729
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US and European postmarket clinical data requirements.
    Donawa M
    Med Device Technol; 2005 Mar; 16(2):19-21. PubMed ID: 15828495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical device preemption after Medtronic, Inc. v. Lohr.
    Neraas MB
    Food Drug Law J; 1996; 51(4):619-29. PubMed ID: 11797731
    [No Abstract]   [Full Text] [Related]  

  • 6. The need for federal preemption of state tort claims in the context of "new drugs" and premarket-approved medical devices.
    Mottes LM
    Seton Hall Law Rev; 2011; 41(2):723-63. PubMed ID: 21739761
    [No Abstract]   [Full Text] [Related]  

  • 7. Medical device regulation in the United States and the European Union: a comparative study.
    Chai JY
    Food Drug Law J; 2000; 55(1):57-80. PubMed ID: 12296349
    [No Abstract]   [Full Text] [Related]  

  • 8. Premarket approval and federal preemption of product liability claims in the wake of Medtronic, Inc. v. Lohr.
    Jarcho DG
    Food Drug Law J; 1996; 51(4):613-8. PubMed ID: 11797730
    [No Abstract]   [Full Text] [Related]  

  • 9. An assessment of the regulations on medical devices in the European Union.
    Frank S
    Food Drug Law J; 2001; 56(1):99-122. PubMed ID: 11942353
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmaceuticals and medical devices: medical devices. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-35. PubMed ID: 23297445
    [No Abstract]   [Full Text] [Related]  

  • 11. Medical device development: from prototype to regulatory approval.
    Kaplan AV; Baim DS; Smith JJ; Feigal DA; Simons M; Jefferys D; Fogarty TJ; Kuntz RE; Leon MB
    Circulation; 2004 Jun; 109(25):3068-72. PubMed ID: 15226221
    [No Abstract]   [Full Text] [Related]  

  • 12. Remarks by the Commissioner of Food and Drugs at the twentieth anniversary celebration of the 1976 Medical Device Amendments.
    Kessler DA
    Food Drug Law J; 1996; 51(4):501-3. PubMed ID: 11797727
    [No Abstract]   [Full Text] [Related]  

  • 13. An important step forward in the global harmonisation of premarket review programmes.
    Donawa M
    Med Device Technol; 2001 Sep; 12(7):28-30. PubMed ID: 12938557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remarks by the Honorable Paul Rogers at the twentieth anniversary celebration of the 1976 Medical Device Amendments.
    Rogers PG
    Food Drug Law J; 1996; 51(4):505-7. PubMed ID: 11797728
    [No Abstract]   [Full Text] [Related]  

  • 15. Food and Drug Administration control of medical devices: an inescapable intrusion and stimulus for adaptation.
    Friedman EA
    ASAIO J; 1998; 44(4):239-40. PubMed ID: 9682946
    [No Abstract]   [Full Text] [Related]  

  • 16. The IVD directive: late-phase practicalities.
    Johnson P; Walker R
    Med Device Technol; 2003 Nov; 14(9):35-6. PubMed ID: 14682022
    [No Abstract]   [Full Text] [Related]  

  • 17. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
    Leghorn J; Brophy E; Rother P
    Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceuticals and medical devices: medical devices. Year end issue brief.
    Tiffany S
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-19. PubMed ID: 18345548
    [No Abstract]   [Full Text] [Related]  

  • 19. Defending substantial equivalence: an argument for the continuing validity of the 510(k) premarket notification process.
    Flaherty JM
    Food Drug Law J; 2008; 63(4):901-27. PubMed ID: 19601388
    [No Abstract]   [Full Text] [Related]  

  • 20. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.